Cost-effectiveness Analyses for the Prevention of Acute Kidney Injury in Patients Undergoing Cardiac Surgery in the UK

Overview

Multi-centre retrospective analysis of prospectively collected data with propensity matched scoring groups (AKI v/s non-AKI). Data collection from databases (or their equivalent): PATS Dendrite, Electronic Medical Records, TD-web (results Portal), MedTrack (ICU database), iSite (Radiology), SPY (Long-term status)

1.1 BACKGROUND Cardiac surgery associated acute kidney injury (CSA-AKI) is reported in 25-40% of patients. This variability is due to a spectrum of definitions used to classify AKI. AKI definition and staging are based on the Risk, Injury, Failure, Loss, End-stage kidney disease (RIFLE) criteria and the Acute Kidney Injury Network (AKIN) criteria, which have been further refined in the Kidney Disease: Improving Global Outcomes (KDIGO) AKI work group guidelines. It is now customary to use the KDIGO definition or its modified version - the AKIN consensus criteria. The development of AKI in the post-op cardiac surgery setting is associated with significant morbidity, mortality, prolonged intensive care (ICU) \& in-hospital stays, increased treatment costs and poorer long-term survival and quality of life. Till now, no satisfactory strategy has been successful in preventing CSA-AKI despite the pre-operative knowledge of those patients who are at risk of developing it. RenalGuard Therapy® (Cardiorenal Systems, Boston, USA) is an automated fluid management system which measures the volume of urine output and enables the physician to set a personalized, instantaneous fluid replacement rate based on the measured urine output. The RenalGuard Therapy® is comprised of a console, a single-use sterile IV infusion set, urine collection set and a cart. The console is a microcontroller device that has a means for measuring urine output and automatically controls the hydration infusion pump based on the measured urine output and clinician settings. The system is designed for infusion of hydration solutions only. The patient is connected to the console by the IV Infusion set connected to the patient's peripheral IV cannula and the urine collection set connected to the patient's indwelling Foley urinary catheter. The console continuously monitors urine production by measuring the weight of urine in the collection set, converts the urine weight to volume and then, automatically infuses the pre-set volume of hydration fluid to compensate for this output. The system is placed on a cart that is designed to hold the console, infusion set, and urine collection set. Safety mechanisms and patient's protection have been designed and incorporated into the RenalGuard Therapy® to support appropriate balance and rates of IV infusion without fluid overloading or dehydrating the patient. The use of the RenalGuard® Therapy was initially investigated at reducing AKI in patients at risk of contrast-induced nephropathy (CIN) when undergoing either percutaneous coronary intervention (PCI) or transcatheter aortic valve implantation (TAVI). These studies showed that in patients with chronic kidney disease, the RenalGuard® Therapy reduced the incidence of AKI by 60 to 75% as compared to controls. The use of the RenalGuard® Therapy in patients undergoing cardiac surgery has only been reported recently. The recent RCT data showed that in patients at risk of developing AKI during cardiac surgery, the RenalGuard® Therapy reduced CSA-AKI rate from 20.9% to 10%. 1.2 RATIONALE FOR CURRENT STUDY AKI is known to be associated with significant costs in healthcare delivery in patients undergoing cardiac surgery. It is estimated that AKI in that group of patients could increase costs by $19,212. In a more recent study published in 2018, the estimated additional cost for AKI post cardiac surgery was reported at $38,358 with a 10-fold increase in mortality (13.9% vs 1.3%) as well as a doubling in the in-hospital stay (mean 18.2 vs 8.6 days) when compared to non-AKI patients. ICU stay has also been reported to be prolonged in patients, post CABG, who developed AKI (mean 5.5 vs 2.2 days). The KIDNEY study confirmed the clinical benefit for the RenalGuard® Therapy. However, the RenalGuard® Therapy does come at a cost and no cost-effectiveness data is currently available in the literature. It is important within the UK NHS setting to assess whether this clinical benefit to the patient has also some cost-effectiveness value attached to it, given that RenalGuard Therapy is marketed at €1,000 per patient in Europe. 2\. STUDY OBJECTIVES Primary objective: Cost-effectiveness assessments using QALY gained \& ICER, with the use of the RenalGuard® Therapy for the reduction of CSA-AKI in patients undergoing cardiac surgery. Secondary objectives: CSA-AKI incidence (as defined by modified KDIGO), ICU \& in-hospital stays, costs of ICU and in-hospital stays and survival rates (index admission and follow-up at the time of the study), best cost-effectiveness sub-group(s). 3\. STUDY DESIGN This is a multi-centre, propensity-matched, retrospective study involving patients who developed AKI after cardiac surgery (CSA-AKI) compared to 1:1 propensity-matched scoring non-AKI patients. It involves retrieving patient's clinical data which was prospectively recorded during the patients stay when they underwent cardiac surgery at various cardiac surgery centres in the UK. The data are currently within the PATS Dendrite, Electronic Medical Records, TD-web (results Portal), MedTrack (ICU database), iSite (Radiology), SPY (Long-term status) databases, or their equivalents. The PATS dendrite database records pre-op, intra-op and post-op data pertaining to patient characteristics, operative details, ICU and ward stay including complications. Data recorded include date of operation, patient's age, body mass index \& gender, risks factors (diabetes, left ventricular function, urgency of procedure), type of procedure, Log Euroscore, cardiopulmonary bypass time, date of extubation, need for inotropes, any complications (respiratory including additional respiratory support, re-exploration, arrhythmias, neurological dysfunction, renal dysfunction, blood transfusion, gastro-intestinal problems), date of ICU discharge, ICU re-admission, date of hospital discharge, patient status at time of discharge and discharge destination. This data is independently verified by the cardiac audit personnel and then the core data is submitted to NICOR from where surgeon-specific and Unit-specific mortality data is confirmed and published on the DoH/SCTS website. The MedTrack Database records the patient's complications and length of stay on the ICU. The iSite details all the radiological investigations while the TD-Web includes all the investigations results (e.g. blood analysis). Data on all databases are recorded contemporaneously. The Clinical Web Portal (Electronic Medical Records) will be used to cross check this information. Some data may need to be retrieved from the medical records. Survival data will be retrieved from the SPY database while hospital cost data will be requested from the hospital finance department. This study (data collection) will run over a period of six months. Thereafter, data analysis \& interpretation, manuscript writing \& publication may take up to another six months.

Conditions

Interventions

Eligibility

Locations (1)

Outcomes